Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ferrimannitol ovalbumin is an iron supplement used for the treatment and prevention of iron deficiency anemia. It is a complex adduct formed between ovalbumin (a protein derived from egg white) and Fe(III)-mannitol, resulting in a water-soluble compound that delivers trivalent iron. The drug corrects hematological variables altered by loss or shortage of iron, making it useful as an oral haematinic agent. The mechanism involves providing bioavailable trivalent iron to support hemoglobin synthesis and red blood cell production[1][2][3][4][5]. The compound has been formulated into solid dosage forms such as tablets to improve patient compliance and reduce the unpleasant metallic taste associated with many oral iron supplements[2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ferrimannitol ovalbumin.